Guerbet LLC, the US affiliate of Guerbet, a global leader in medical imaging, announced a recent boom for DOTAREM (gadoterate meglumine) injection.

December 7, 2021 — Guerbet LLC, the US affiliate of Guerbet, a global leader in medical imaging, announced a recent boom for DOTAREM (gadoterate meglumine) injection. DOTAREM’s significant increases come in the face of the continued presence of a pandemic and supply chain disruptions. The company shipped more doses of its flagship MRI contrast agent in October than in any other monthly period since its US release in 2013.

“We are making great strides in the U.S. with our flagship product,” said Thomas McLaughlin, Vice President of North America. “DOTAREM is a trusted solution that supports our commitment to radiologists in the MR suite. There's no doubt that our macrocyclic and ionic molecule has the highest kinetic and thermodynamic stability among currently approved GBCAs.”

Since its release in 1989, DOTAREM (gadoterate meglumine) Injection has been a leading MR contrast agent in Europe, Asia, Africa, the Middle East, and South America. DOTAREM received U.S. Food and Drug Administration (FDA) approval in 2013, becoming the first macrocyclic, ionic gadolinium-based contrast agent (GBCA) in the United States. It has become the No. 2 MR contrast agent in the US and is currently No. 1 in the world, with more than 120 million doses delivered in 70 countries.

The news of DOTAREM’s success follows a long legacy of Guerbet committing itself to the radiology community. In the midst of the COVID-19 crisis in 2020, the company mobilized partners and colleagues across the industry to continue making treatment-critical products available to healthcare professionals. In addition, the organization continually supports the industry with research, education, and development, as is the case in their participation in the annual Radiological Society of North America (RSNA) Conference.

For information: www.guerbet.com/en-us/products-solutions/contrast-agents/dotarem-gadoterate-meglumine-injection/

Related RSNA2021 content

Related Content

News | Coronavirus (COVID-19)

January 14, 2022 — The COVID-19 pandemic took the world by storm in early 2020 and has become since then the leading ...

Time January 14, 2022
arrow
Videos | Artificial Intelligence

Here are two examples of artificial intelligence (AI) driven pulmonary embolism (PE) response team apps featured by ...

Time January 13, 2022
arrow
News | Radiology Business

January 13, 2022 — The Board of Directors of Esaote, a leading Italian company in the biomedical sector – in ultrasound ...

Time January 13, 2022
arrow
Videos | Enterprise Imaging

Steve Holloway, company director at Signify Research, explains the trends he has seen over the past couple years in ...

Time January 13, 2022
arrow
News | Pediatric Imaging

January 12, 2022 — According to an article in ARRS’ American Journal of Roentgenology (AJR), whole-spine MRI commonly ...

Time January 12, 2022
arrow
News | Radiology Imaging

January 12, 2022 — Machine-learning methods are being actively developed for computed imaging systems like magnetic ...

Time January 12, 2022
arrow
News | Breast Imaging

January 11, 2022 — Less-experienced radiologists are more likely to recommend additional imaging for women undergoing ...

Time January 11, 2022
arrow
News | Computed Tomography (CT)

January 6, 2022 — Royal Philips announced new additions to its CT imaging portfolio at the Radiological Society of North ...

Time January 06, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

January 5, 2022 — According to an article in ARRS’ American Journal of Roentgenology (AJR), brain volume measurements in ...

Time January 05, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

January 5, 2022 — A new neuroimaging technique can detect biochemical changes in the brains of people with multiple ...

Time January 05, 2022
arrow
Subscribe Now